About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

WITHDRAWNPhase 4NCT00625079

Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil

Pulmonary Arterial Hypertension (PAH) in the setting of Idiopathic Pulmonary Fibrosis(IPF)is a risk factor for morbidity and mortality in the peri-lung transplant(LT) setting. Currently there is no si...

Lead sponsor: University of California, Los Angeles•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of California, Los Angeles

Collaborators

Pfizer

The purpose of this study is to evaluate the use of sildenafil in patients with pulmonary fibrosis and PH being considered for lung transplantation. We hypothesize that not only will sildenafil improve functionality and QOL in the pre-transplant setting but it may also improve primary graft dysfunction after lung transplantation.

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with Idiopathic Pulmonary Fibrosis referred for lung transplantation at our medical center
•Minimal 6 minute walk distance of 50 meters; must be able to conduct supine exercise during heart catheterization

Exclusion Criteria

•Non ambulatory
•Prior adverse reaction/allergy to sildenafil or other PDE-5 Inhibitors
•Any other pulmonary vasodilator within one month of enrollment

Related studies

RECRUITINGPhase 3

An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

NCT07365332 · Pulmonary Arterial Hypertension

RECRUITINGPhase 3

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029 · Pulmonary Arterial Hypertension

RECRUITINGPhase 2

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383 · Interstitial Lung Disease, Pulmonary Fibrosis

RECRUITINGPhase 1/2

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension

RECRUITINGPhase 2

A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients

NCT05139719 · Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 1, 2018Terms

Trial snapshot

StatusWITHDRAWN

PhasePHASE4

Enrollment—

Start dateFeb 2007

Last updatedMay 1, 2018

Condition

Pulmonary Arterial Hypertension Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Pulmonary Hypertension

Locations shown

David Geffen School of Medicine UCLA

Los Angeles, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 1, 2018Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions